Darolutamide

Darolutamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Darolutamide 研究

• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  III 期招募中美国Puerto RicoNCT07723248

• An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

  不适用招募中South KoreaNCT06334120

• Study of ORIC-944 in Patients With Metastatic Prostate Cancer

  I 期招募中美国澳大利亚西班牙英国NCT05413421

• Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  III 期招募中丹麦法国西班牙NCT05974774

• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  III 期招募中比利时挪威瑞典瑞士NCT03903835

• Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  III 期招募中美国奥地利Brazil加拿大NCT07711002

• SNV1521 in Participants With Advanced Solid Tumors

  I 期招募中美国澳大利亚比利时加拿大NCT06220864

• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

  III 期招募中法国NCT06496581

• Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

  III 期招募中英国NCT07751133

• Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  不适用招募中西班牙NCT06724159

• Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

  I 期招募中美国NCT06631521

• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

  II 期招募中美国NCT07142551

• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  III 期招募中美国加拿大MexicoUruguayNCT06592924

• Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  I 期 / II 期招募中美国NCT04946370

• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  I 期招募中美国澳大利亚中国法国NCT07244341

• Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

  I 期 / II 期招募中美国NCT07182279

• Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC

  II 期招募中中国NCT07503379

• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  II 期招募中美国NCT06844383

• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  III 期招募中英国NCT06320067

• How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

  不适用招募中德国NCT07395804

• Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

  III 期招募中法国NCT06276465

• Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

  III 期招募中中国NCT06350825

• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

  II 期招募中荷兰NCT05762536

• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

  II 期招募中美国NCT07016399

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。